L-Carnitine is not a peptide. It is a small, highly water-soluble zwitterionic molecule (betaine-type) containing a permanently charged quaternary ammonium group and a carboxylate group that is deprotonated at neutral pH.

Its CAS number is 541-15-1, its molecular formula is C7H15NO3, its average molecular weight is 161.20 g/mol, its monoisotopic exact mass is 161.10519334 Da, and its PubChem CID is 10917.[1] The compound is the (R)-enantiomer with one defined stereocenter, a calculated XLogP3-AA of −0.2, a topological polar surface area of 60.4 Ų, and one hydrogen-bond donor and three hydrogen-bond acceptors.
The free-acid carboxyl group has a pKa of approximately 3.8. L-Carnitine is a hygroscopic, white crystalline powder with a melting point of approximately 195–198 °C (with decomposition at ~197 °C).[1]
In laboratory studies, L-carnitine is best known for its part in the carnitine shuttle. This system helps move long-chain fatty acyl groups into the mitochondrial matrix, where they can enter beta-oxidation.
The carnitine shuttle and its associated enzymes are reviewed in detail by Longo and colleagues.[2]
Basic Information
| Property | Value |
|---|---|
| Compound type | Non-peptide small molecule; endogenous metabolite; biochemical research reagent |
| CAS number | 541-15-1 |
| PubChem CID | 10917 |
| Molecular formula | C7H15NO3 |
| Average molecular weight | 161.20 g/mol |
| Monoisotopic exact mass | 161.10519334 Da[1] |
| pKa (carboxyl group) | ~3.8[1] |
| Stereochemistry | L-carnitine, (R)-configuration; one defined stereocenter[1] |
| Peptide sequence | Not applicable—L-carnitine is not a peptide and has no amino-acid chain or peptide bonds |
| Storage | Follow the storage condition printed on the product label, COA, or SDS |
L-Carnitine is highly water-soluble (up to ~2500 mg/mL reported in DrugBank). The free-acid form should be distinguished from L-carnitine hydrochloride (MW ~197.66 g/mol) and L-carnitine tartrate, which have different molecular weights and stoichiometries.
Do not confuse L-carnitine (CID 10917) with DL-carnitine (CID 288), which is the racemic mixture.[3]
How the Carnitine Shuttle Works
Long-chain fatty acyl-CoA does not freely cross the inner mitochondrial membrane. The carnitine shuttle moves the acyl group in three main steps, as described in detail by Indiveri and colleagues in their structural and functional review of the mitochondrial carnitine/acylcarnitine carrier.[4]
- CPT1 forms acylcarnitine. Carnitine palmitoyltransferase 1A and 1B (CPT1A and CPT1B) are located on the outer mitochondrial membrane.They transfer a long-chain acyl group from acyl-CoA to L-carnitine, producing acylcarnitine and free CoA.[4]
- CACT carries it across the inner membrane. Carnitine-acylcarnitine translocase (CACT, encoded by SLC25A20) is an inner mitochondrial membrane transporter that exchanges acylcarnitine moving inward for free carnitine moving outward.[4]
- CPT2 reforms acyl-CoA. On the matrix side of the inner membrane, CPT2 transfers the acyl group from acylcarnitine back to CoA.The resulting acyl-CoA can then enter beta-oxidation.
CPT1C differs from CPT1A and CPT1B in both subcellular location and catalytic function. Sierra and colleagues reported that CPT1C is predominantly localised to the endoplasmic reticulum in neuronal cells rather than to mitochondria, and its catalytic efficiency for carnitine palmitoyltransferase activity was approximately 20- to 300-fold lower than that of CPT1A.
CPT1C should therefore not be described as functionally equivalent to the mitochondrial CPT1 isoforms.[6]
Medium-Chain and Short-Chain Fatty-Acid Handling
The requirement for L-carnitine in fatty-acid oxidation depends on the fatty-acid chain length and the tissue. Pereyra and colleagues studied free medium-chain fatty-acid (octanoate) oxidation in mouse tissue homogenates and found that it was largely independent of L-carnitine in liver and kidney but showed carnitine dependence in heart and skeletal muscle.
Medium-chain fatty-acid handling should therefore not be described by one simple rule—the need for L-carnitine changes with the tissue and the experimental model.[5]
L-Carnitine also takes part in short-chain acyl-group transfer. Carnitine acetyltransferase (CrAT) can reversibly move an acetyl group between acetyl-CoA and carnitine.
Muoio and colleagues studied muscle-specific CrAT knockout mice and reported that CrAT deletion compromised glucose tolerance and metabolic flexibility. In isolated mitochondria and mouse muscle models, this reaction has been studied as one way cells maintain free CoA availability when acetyl-CoA accumulates.[7]
Cellular Uptake and Transport
In many mammalian tissues, high-affinity cellular uptake of L-carnitine is primarily mediated by OCTN2, encoded by the SLC22A5 gene. Wu and colleagues characterised OCTN2 as a high-affinity, sodium-dependent carnitine transporter and described its tissue distribution pattern.
The measured transport rate and Km can differ between cell systems, so one value should not be treated as universal.[8]
Common Research Uses
- Fatty-acid oxidation assays. Some extracellular-flux protocols add L-carnitine when testing long-chain fatty-acid-supported respiration.A published Seahorse XF protocol for neonatal mouse cardiomyocytes (P0–P1, plated at 25,000 cells/well) used a 50 mM L-carnitine stock (stored at −20 °C, stable for 6–12 months), diluted to a final working concentration of 0.5 mM in FAO assay medium containing palmitate-BSA (1 mM palmitate / 0.2 mM fatty-acid-free BSA) as the substrate. The FAO medium was Krebs-Henseleit buffer supplemented with 0.5 mM L-carnitine and 50 mM HEPES.Under this protocol, basal OCR for healthy cells was approximately 100–200 pmol O2/min, and the CPT1B inhibitor etomoxir (40 µM) was used to distinguish exogenous from endogenous fatty-acid oxidation. These values belong to that specific method and should not be copied into unrelated experiments without testing.[9]
- Acylcarnitine measurement. LC-MS/MS methods can quantify free carnitine and individual acylcarnitine species.Giesbertz and colleagues developed and validated an LC-MS/MS method covering 56 acylcarnitine species (C2–C18) with isomer separation, using a Zorbax Eclipse XDB-C18 column and scheduled MRM on a QTRAP 5500 instrument. The method was validated for plasma (10 µL) and liver tissue (40 mg), with calibration r² > 0.99 for all analytes, intra-day and inter-day precision CVs below 10% for high-abundance species, and accuracy of 89–120% for plasma and 81–108% for liver.The authors noted that matrix effects in muscle, heart, and kidney were comparable to those in liver, but other matrices—including cell extracts and culture media—require separate matrix-matched validation, appropriate extraction procedures, and suitable internal standards. Results should be interpreted by examining the specific compounds measured and the study model, not by treating one ratio as a universal measure of mitochondrial function.[10]
- Mitochondrial and peroxisomal studies. Acylcarnitine changes can come from more than one pathway.Houten and colleagues reviewed the metabolic interactions between peroxisomes and mitochondria with a focus on acylcarnitine metabolism. Peroxisomes and mitochondria both take part in fatty-acid handling, so a change in an acylcarnitine profile should not automatically be assigned to one enzyme.[11]
- Direct enzyme tests and whole-pathway tests are different. A direct CPT assay measures the CPT reaction itself.Oxygen use, carbon dioxide release, or acid-soluble products reflect several steps together, including transport and later beta-oxidation. These results should not be labeled as direct CPT1 activity unless the method was designed to isolate that step.
Laboratory Preparation
The calculations below apply only to anhydrous free-form L-carnitine (CAS 541-15-1, MW 161.20 g/mol). Do not use this molecular weight for L-carnitine hydrochloride (~197.66 g/mol), L-carnitine tartrate, a hydrated form, or another salt.
Correct the weighed mass for assay (peptide-content-equivalent or purity-adjusted value) and water content when those data are available from the batch-specific COA.
Use this formula to calculate the amount of L-carnitine needed:
Mass (g) = concentration (mol/L) × final volume (L) × molecular weight (g/mol)
| Stock Concentration | L-Carnitine (free-form, MW 161.20) for 10 mL | Equivalent Mass Concentration |
|---|---|---|
| 0.1 M | 0.1612 g | 16.12 mg/mL |
| 0.5 M | 0.8060 g | 80.60 mg/mL |
The calculation can be mathematically correct while the solution is still unsuitable for an experiment. Water, PBS, and assay buffer should not be treated as interchangeable without testing.
The pH of L-carnitine solutions varies with concentration and the specific batch; one supplier, for example, reports a pH range of 6.5–8.5 for a 50 g/L aqueous solution. Check the final pH, osmolality, salt level, vehicle volume, and compatibility with the assay before use.
Keep the dry reagent tightly closed and protect it from moisture—L-carnitine is notably hygroscopic. If the container was stored cold, let it reach room temperature while still sealed before opening to reduce moisture condensation.
For prepared solutions, use fresh material or a storage period supported by actual stability data. Filtration can reduce microbial contamination, but it does not prove that the solution remains chemically stable.
How to Read the COA
A COA applies only to the batch shown on the document. A well-constructed batch-specific COA typically identifies the product and lot and reports the applicable test items, specifications, results, methods or method references, and authorisation information.
The exact content depends on the supplier’s quality system and the claimed product grade; there is no single mandatory COA format for all research-use-only reagents.
HPLC chromatographic purity (often reported as area-normalised peak-area percentage) reflects the distribution of detectable components under a specific chromatographic method. It is not the same as an assay or content value, and it does not automatically account for water, inorganic salts, non-UV-absorbing impurities, enantiomeric purity, or residual solvents.
These attributes may require separate tests. For regulated pharmaceutical or GMP-grade materials, analytical method validation may follow applicable ICH principles such as ICH Q2(R2).
For general research-use-only reagents, these principles may serve as quality references but are not automatically mandatory regulatory requirements.[12]
| COA Item | What It Shows |
|---|---|
| Identity | Checks whether the material matches the stated compound; the method may include MS, NMR, IR, or another suitable identity test |
| HPLC chromatographic purity | Shows the relative peak-area distribution of detectable components under the stated chromatographic method; does not represent absolute mass content or cover non-chromatographic quality attributes |
| Assay or content | Measures the amount of the target compound in the sample; the result may be reported on an as-is, dried, anhydrous, or solvent-free basis, and this basis should be stated |
| Chiral purity | Checks the proportion of the required L-enantiomer when this is part of the specification |
| Water or loss on drying | Checks moisture or volatile mass under the stated method; relevant for hygroscopic materials such as L-carnitine |
| Residual solvents | Checks solvents that may remain from manufacturing or purification; testing should be based on solvents used or reasonably expected from the process. Gas chromatography is commonly used. For GMP-grade materials, applicable ICH Q3C(R9) limits may be referenced, but these are pharmaceutical regulatory limits and are not automatically mandatory for all RUO reagents.[13] |
Important: A passing COA describes laboratory raw-material quality under the listed tests. It does not prove human or veterinary safety, medical effectiveness, or suitability for administration.
Key Points
- L-Carnitine is a non-peptide small molecule (zwitterionic betaine, C7H15NO3, 161.20 g/mol). Peptide-specific quality parameters do not apply.
- It carries long-chain acyl groups through the CPT1–CACT–CPT2 shuttle into the mitochondrial matrix.
- CPT1C is localised to the endoplasmic reticulum in neuronal cells and has approximately 20- to 300-fold lower catalytic efficiency than CPT1A.[6]
- Medium-chain fatty-acid handling varies by tissue: in mouse tissue homogenates, octanoate oxidation was largely carnitine-independent in liver and kidney but carnitine-dependent in heart and skeletal muscle.[5]
- Free-form L-carnitine (MW 161.20) must be distinguished from hydrochloride (~197.66 g/mol), tartrate, and hydrated forms for accurate molar calculations.
- HPLC chromatographic purity and assay (content) are separate quality attributes and should not be merged on a COA.
- All conclusions must stay within the in-vitro, isolated-organelle, or laboratory animal model that was tested.
References
- NIH PubChem. L-Carnitine, CID 10917 (C7H15NO3, 161.20 g/mol, CAS 541-15-1, exact mass 161.10519334 Da, pKa ~3.8, m.p. 195–198 °C). https://pubchem.ncbi.nlm.nih.gov/compound/10917
- Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422-2435. doi:10.1016/j.bbamcr.2016.01.023. https://pmc.ncbi.nlm.nih.gov/articles/PMC4967041/
- NIH PubChem. DL-Carnitine, CID 288. https://pubchem.ncbi.nlm.nih.gov/compound/Carnitine
- Indiveri C, Iacobazzi V, Tonazzi A, et al. The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med. 2011;32(4-6):223-233. doi:10.1016/j.mam.2011.10.008. https://pubmed.ncbi.nlm.nih.gov/22020113/
- Pereyra AS, Harris KL, Soepriatna AH, et al. Medium-chain fatty acid oxidation is independent of L-carnitine in liver and kidney but not in heart and skeletal muscle. Am J Physiol Gastrointest Liver Physiol. 2023;325(4):G287-G299. doi:10.1152/ajpgi.00112.2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10642992/
- Sierra AY, Gratacós E, Carrasco P, et al. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem. 2008;283(11):6878-6885. doi:10.1074/jbc.M707965200. https://pubmed.ncbi.nlm.nih.gov/18192268/
- Muoio DM, Noland RC, Kovalik JP, et al. Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab. 2012;15(5):764-777. doi:10.1016/j.cmet.2012.04.005. https://pmc.ncbi.nlm.nih.gov/articles/PMC3348515/
- Wu X, Prasad PD, Leibach FH, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999;290(3):1482-1492. https://pubmed.ncbi.nlm.nih.gov/10454528/
- Angelini A, Pi X, Xie L. Evaluation of long-chain fatty acid respiration in neonatal mouse cardiomyocytes using Seahorse instrument. STAR Protoc. 2022;3(2):101318. doi:10.1016/j.xpro.2022.101318. https://pmc.ncbi.nlm.nih.gov/articles/PMC9120230/
- Giesbertz P, Ecker J, Haag A, Spanier B, Daniel H. An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues. J Lipid Res. 2015;56(10):2029-2039. doi:10.1194/jlr.D061721. https://pmc.ncbi.nlm.nih.gov/articles/PMC4583086/
- Houten SM, Wanders RJA, Ranea-Robles P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165720. doi:10.1016/j.bbadis.2020.165720. https://pmc.ncbi.nlm.nih.gov/articles/PMC7146961/
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. 2023. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
- International Council for Harmonisation. ICH Q3C(R9): Guideline for Residual Solvents. Step 4, January 2024. https://database.ich.org/sites/default/files/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf
Research Use Only Disclaimer
Research Use Only: The L-carnitine product described on this page is supplied for laboratory research purposes only and is not approved for human or veterinary use. This article summarises published preclinical findings and analytical-quality considerations.
It does not provide medical advice, dosing instructions, administration guidance, or preparation procedures.